...A. And our flagship product, mitapivat, which is known commercially as PYRUKYND, we were really pleased to have launched PYRUKYND back in early 2022 for an ultra-rare indication called PKD or pyruvate kinase deficiency and that has served as a wonderful platform for us to build up commercial capabilities in rare but secondly, also to see how PYRUKYND performs in the rare space, in the real world. B. In January, we reported out our ENERGIZE pivotal Phase III study and ENERGIZE is focused on the non-transfusion-dependent thalassemia patients and why that's important is because in the U.S., that's about 2/3 of the population. C. And we announced earlier this month that we're expecting that top line data set actually Q2, the quarter that we're in right now. D. We announced the top line results of RISE UP Phase II data for sickle cell, we hit with both doses tested, statistical significance in hemoglobin improvement. E. We ended the first quarter with approximately $714 million on the balance...
